Next Generation Sequencing Market
Next Generation Sequencing Market Size, Share, Competitive Landscape and Trend Analysis Report by Product Type, Technology, Application and End-User: Global Opportunity and Industry Forecast (2025-2030)
Report ID:
1097
Industry:
Healthcare
Published on:
Mar 2025
Next Generation Sequencing Market Summary
Global Next Generation Sequencing Market was a value of USD 10.30 Billion in 2025 and expected to reached at USD 24.07 Billion by 2032, with a CAGR of 15.2 % during the forecast period (2025-2032).
Next Generation Sequencing Market Size, Share, Competitive Landscape and Trend Analysis Report by Product Type (Instruments, Reagents & Consumables, Services), by Technology (Whole Genome Sequencing, Targeted Sequencing & Re-sequencing, Whole Exome Sequencing, RNA Sequencing, Chip Sequencing, De Novo Sequencing, Methyl Sequencing), by Application (Drug Discovery/Personalized Medicine, Genetic Screening
Diagnostics/Infectious Diseases, Agricultural & Animal Research, Others) by End-User (Healthcare Institutions, Academics, Biotech & Pharma Firms, Others)
Next Generation Sequencing Industry Trends and Analytical Insights -
North America Next Generation Sequencing Market was the largest revenue generating region market in year 2025, with market share accounted for 45.60 %.
In 2025, By Technology, Targeted Sequencing & Re-sequencing dominated the Next Generation Sequencing Market, accounted for 42.5% market shares.
Leading Key players for Next Generation Sequencing Market in 2025 was Illumina, Inc., Thermo Fisher Scientific, Inc., F. Hoffmann-La Roche Ltd. (Roche), QIAGEN N.V. and Agilent Technologies, Inc.
Market Size & Forecast
Market Size 2025: USD 10.30 Billion
Projected Market Size 2032: USD 24.07 Billion
CAGR (2025-2032): 15.2%
North America: Dominated market in 2025
Next Generation Sequencing Market Overview
The term "Next Generation Sequencing Market" was referring to the use of cutting-edge sequencing technologies to quickly and efficiently provide accurate analysis of DNA and RNA sequences in a professional manner. These Next Gen Sequencing technologies were being used frequently for a variety of applications, including diagnostic medicine, drug development, agriculture (agricultural genomics), and personalized healthcare, where large numbers of genomic data sets were being processed. The worldwide utilization of Next Generation Sequencing technologies was continuing to increase dramatically through 2024, with approximately 45 million sequencing runs being performed annually, indicating that the use of Next Gen Sequencing was being embraced as the standard method for analysing DNA and RNA sequences by healthcare and academic research organizations. Another significant driver of the Next Generation Sequencing Market was the trending decline that was occurring in the cost of sequencing new genomes; nearly $2024 per genome in 2015, with a projected $600 per genome in 2024. Therefore, as a result of rapid advances that were taking place in the capability and price of Next Generation Sequencing technology, genomic testing/remediation was becoming available to the majority of people.
The Next Generation Sequencing market was benefiting from rapid increases in both the number of sequences generated genomic data as well as the volume of sequencing that was occurring globally research versus clinical by 2024, there were more than 45 million sequencing runs being completed globally versus about 32 million runs that were being completed in 2021 for an approximate annual rate of greater than 40% increase in sequence volume per year. Additionally, the Next Generation Sequencing market was experiencing a sizeable decrease in the cost of sequencing – decreasing from around $2024 per genome in 2021 to less than $40% per genome in 2024 providing hospitals and research institutions with greater financial ability to utilize genomic technology for their needs.
The Next Generation Sequencing (NGS) Market was experiencing a strong impact from the growing requirement for precise medication and understanding of genetic disorders. In 2023, approximately 62% of all genomic studies were focusing on oncology-related studies, in which sequencing technologies were being utilized to provide targeted therapies. This writing was being prepared to assist the biotechnology companies, pharmaceutical organizations, research facilities, healthcare organisations, and investors that were looking to gather actionable data regarding the Next Generation Sequencing Market and how it was influencing the following areas: strategic planning, making investment decisions, and how to go about evaluating the adoption of new technology. The report was being developed to be useful to stakeholders who were wanting to learn about the trends towards new technologies, production capacity, and application opportunities that were existing with the NGS Market.
Next Generation Sequencing Market Dynamic’s
Market forces were driving the Next Gen Sequencing market including the increased adoption of genomic technologies that was occurring in healthcare and the life sciences. Throughput of sequencing was improving greatly, while throughput from modern sequencing platforms was exceeding 20,000 genomes that were being processed annually per sequencing system. Clinical applications were expanding rapidly over the last several years, with 20,000 of hospitals in developed nations that were integrating sequencing technologies into diagnostic workflows by 2024. Investment in genomics was greatly impacting the NextGen Sequencing marketplace with global funding that was exceeding $30 billion in 20,000. According to JBI, improvements in the technology were improving the accuracy of sequencing by 20,000. The National Institute of Health (NIH) and the World Health Organization (WHO) were also documenting the increased use of genomic solutions that was occurring in healthcare settings. The purpose of this research document was to provide structured information that was required to support effective decision-making that was pertaining to the Next Generation Sequencing market.
Challenges in the Next Generation Sequencing Market were being made more difficult by high data processing amounts and complex regulations. As data was continuing to grow at a rate of approximately 40% each year, the demand was also being placed on infrastructure. Additionally, shortages of skilled workers, particularly in bioinformatics, were continuing to limit the ability to adopt new technology, especially where bioinformatics expertise was being required to interpret data. Emerging opportunities in cloud-based sequencing platforms were facilitating improved efficiencies of at least 40% for the management of sequencing data. The Next Generation Sequencing Market was experiencing further growth in developing countries where the digitization of healthcare was rapidly increasing. Improved service delivery and access was being made possible through partnerships between sequencing technology providers and healthcare institutions, thus reinforcing the strengths of service delivery and increasing access in the Next Generation Sequencing Market.
Newly emerging trends in the Next Generation Sequencing Market were exhibiting significant collaborative and innovative efforts from companies within this space. Novel portable sequencing devices were being developed by several companies that were reducing the processing time of sequencing samples by up to 50%. The use of artificial intelligence (AI) in combination with NGS technology was improving accuracy of data analysis by approximately 50% and was promoting better clinical outcomes. As per JBI, greater than 50% strategic partnerships or collaborations were being planned for the year 2024 between various biotechnology companies and research institutions. JBI noted that the continuing development of these technologies was enabling the advancement of personalized medicine and was accelerating genomic research. Data collected from a variety of sources (e.g., Genome Research Consortium, OECD) was suggesting that there was an ongoing increase in the availability and utilization of sequencing technologies, which was supporting the anticipated growth of the Next Generation Sequencing Market.
Next Generation Sequencing Market Segment Analysis
The Next Generation Sequencing Market is segmented into Product Type, Technology, Application and End-User.
By Technology
Based on Technology segment the Next Generation Sequencing Market is segmented into Whole Genome Sequencing, Targeted Sequencing & Re-sequencing, Whole Exome Sequencing, RNA Sequencing, Chip Sequencing, De Novo Sequencing and Methyl Sequencing. Targeted Sequencing & Re-sequencing has the largest market share of Next Generation Sequencing Market, accounted for 42.5% in 2025. This dominance was driven by its wide clinical adoption, economical nature, and capability of providing focused, high-depth insights which were vital for oncology, inherited disease testing, and infectious disease analysis. Targeted panels need 70-80% less sequencing volume than whole genome workflows, thus, they were quicker, more cost-effective, and have a simpler data interpretation. The growing utilization of them in standard diagnostics, as a result of regulatory-approved panels and solid reimbursement coverage, has definitively targeted sequencing as the leading technology of 2025.
By Application
Based on Application Segment, the Next Generation Sequencing Market is segmented into Drug Discovery/Personalized Medicine, Genetic Screening, Diagnostics/Infectious Diseases, Agricultural & Animal Research and Others. Within the Application segment, Diagnostics/Infectious Diseases appears the dominated sub segment have market share, accounted for 48% in 2025 for Next Generation Sequencing Market. This dominance driven by Sequencing-based tests for oncology diagnostics, hereditary disease detection, and pathogen surveillance were the main clinical applications that rapidly adopted the tests. The number of clinical Next Generation Sequencing tests increased very fast as a result of the demand for liquid biopsies, rapid pathogen identification, and companion diagnostics supporting targeted therapies. This segment was preferred by hospitals and reference labs because Next Generation Sequencing-enabled diagnostics are more sensitive, faster in turnaround, and provide richer genomic insights, thus making it the most widely utilized application globally.
Next Generation Sequencing Market Region Analysis
In 2025, the North America Next Generation Sequencing Market dominated global market accounted for 45.60% of market share. This market dominance was mainly owing to the strong clinical adoption of sequencing-based diagnostics in the region, a large number of advanced genomic labs, and the early use of Next Generation Sequencing in the testing of oncology and reproductive health. The U.S. Next Generation Sequencing Industry carried out more than 20 million clinical Next Generation Sequencing tests in the year, which was made possible by the establishment of favourable reimbursement routes and significant investments in precision medicine programs. Besides the presence of major Next Generation Sequencing industry players and strong academic research networks, and the continuous FDA approvals, North America Next Generation Sequencing Market became the most mature and innovation-led market globally and hence, the region solidified its position.
Europe Next Generation Sequencing Market was the second-largest market and was mainly supported by national genome programs and the global adoption of diagnostics in oncology and rare diseases. The total sequencing volume of this market increased by more than 18%, with the UK and Germany was the main contributors to the demand. The Asia-Pacific Next Generation Sequencing Market was the fastest-growing market, a Next Generation Sequencing Market trend mainly influenced by China, Japan, and South Korea, which jointly accounted for over 30% of the global sequencing output as a result of the rapid growth of infrastructure and the availability of low-cost sequencing services. Latin America Next Generation Sequencing Market and the Middle East Next Generation Sequencing Market had shown some potential as a result of the increased adoption of tertiary-care hospitals and a rise in genomic research investments. However, adoption has mainly concentrated in the major urban centers.
Next Generation Sequencing Market Competitive Analysis
Illumina Inc, Thermo Fisher Scientific,Inc, and F. Hoffmann-La Roche Ltd. This trio was at the forefront of the Next Generation Sequencing Industry, and together they had the most significant impact on the global Next Generation Sequencing ecosystem. Illumina remained on top because of its long sequencing platform portfolio, which accounted for more than 65% of the installations of Next Generation Sequencing instruments globally, and was backed by a solid substance ecosystem and data accuracy that was difficult to match. The company Thermo Fisher achieved and kept a good position by providing affordable Ion Torrent systems and a wide clinical adoption in oncology and infectious disease labs. With its strong diagnostics footprint and a growing portfolio of Next Generation Sequencing based assays, Roche continued to be a major player in the clinical genomics field and solidified its dominance.
After the top players, these companies had a major influence to evolve the Next Generation Sequencing Industry in various ways. PacBio, Oxford Nanopore, and 10x Genomics differentiated themselves competitively by innovating in long-read, nanopore, and single-cell sequencing technologies respectively. BGI Genomics positioned itself as a volume-centric service provider. Eurofins and Novogene were the major contributors in spreading sequencing services globally through their extensive laboratory networks. Agilent, QIAGEN, and NEB were instrumental in strengthening the integration of sample prep, library kits, and analysis tools across Next Generation Sequencing workflows. On the other hand, Danaher and Merck KGaA used their life-science portfolios to provide the most needed reagents and instrumentation, thus, they were among the major contributors to a diversified, innovation-driven competitive landscape.
Next Generation Sequencing Market Scope:
Next Generation Sequencing Market Key Players –
Thermo Fisher Scientific, Inc.
QIAGEN N.V.
Agilent Technologies, Inc.
Oxford Nanopore Technologies
BGI Genomics / BGI Group
Eurofins Scientific
Danaher Corporation
Merck KGaA
10x Genomics
New England Biolabs (NEB)
Novogene Co., Ltd.
Frequently Ask Questions –
Who are the major Key players of Next Generation Sequencing Market?
Ans - The Major Key players of Next Generation Sequencing Market are Illumina, Inc., Thermo Fisher Scientific, Inc., F. Hoffmann-La Roche Ltd. (Roche QIAGEN N.V. and Agilent Technologies, Inc.
Which Region accounted highest share of the Next Generation Sequencing Market in 2025?
Ans – North America region accounted highest share of the Next Generation Sequencing Market.
What was the market size of Next Generation Sequencing Market in 2025?
Ans – In 2025, market size of the Next Generation Sequencing Market is USD 10.30 Billion.
Which Segment is expected to lead the market during forecast period?
Ans – Technology Segment was the top segment holds the largest share in Next Generation Sequencing Market during forecast period.
What will be the market size of Next Generation Sequencing Market in 2032?
Ans- The market size of Next Generation Sequencing Market in 2032 will be USD 24.07 Billion.